Psoriasis News

Infliximab biosimilar uptake increased by no more than just 5% annually following the release of its first two biosimilars, but then shot up by 13% to 16% for most patients after a third option emerged, according to data.

Secukinumab was shown to be safe and efficacious in treating psoriasis in patients with skin of color, according to a study.

Patients with moderate to severe psoriasis in hard-to-treat areas of the body who received ixekizumab experienced long-term success over 5 years, according to a study.

Zasocitinib, a potent and selective tyrosine kinase 2 inhibitor, safely and effectively cleared psoriasis in a high proportion of patients, according to a study.

Gaining weight can raise the risk for atopic dermatitis and possibly other immune-mediated skin diseases in children, whereas losing weight can reduce this risk, according to a study.

Otezla is now available in the U.S. for the treatment of moderate to severe plaque psoriasis in children and adolescents aged 6 years and older, Amgen announced in a press release.

Individuals with moderate to severe psoriasis experience work absenteeism more than those with a mild form of the disease, according to a study.

Guselkumab can effectively and safely treat patients with psoriasis for up to 2 years, according to a study.

Calcipotriol/betamethasone dipropionate, or CAL/BDP, combination cream vs. foam had higher satisfaction ratings among patients with psoriasis, suggesting the cream formulation may increase adherence, according to a study.

Artax Biopharma has recruited all 30 patients to a phase 2a clinical trial of AX-158, its investigative Nck modulator for autoimmune diseases, the company announced in a press release.